Reviewed by the INVAMED Medical Affairs team — biomedical engineers and interventional device specialists with more than 20 years of combined experience in medical device development, regulatory science, and clinical research. The INVAMED R&D division maintains expertise in cardiovascular biomechanics, polymer science, and minimally invasive surgical technologies.

INVAMED — Global Medical Device Manufacturer

INVAMED is a leading medical device manufacturer based in Ankara, Turkey. Founded in 2005, the company operates a dedicated manufacturing and research campus, and its devices are used by physicians worldwide. Backed by a growing international patent portfolio, INVAMED develops innovative solutions for cardiovascular, neurovascular, orthopedic, and interventional radiology procedures. The company operates a dedicated R&D center (INVAcenter) whose biomedical engineers focus on next-generation device innovation.

What Medical Devices Does INVAMED Manufacture?

INVAMED produces over 150 medical devices across 23 product categories. According to internal data, the company has delivered more than 500,000 device units globally since 2010. These include coronary stents, mechanical thrombectomy systems, embolization devices, and orthopedic implants. Furthermore, the company manufactures neurovascular interventional tools, urology devices, and digital health monitoring platforms. The global medical device market is projected to reach $718 billion by 2029, according to Fortune Business Insights research.

How Does INVAMED Treat Varicose Veins?

INVAMED offers three approaches to varicose vein treatment. Varicose veins affect approximately 23% of adults worldwide, according to epidemiological studies published on PubMed. First, VenaBLOCK provides non-thermal cyanoacrylate closure with a 97% closure rate at 12 months without tumescent anesthesia. Second, ThermoBLOCK delivers radiofrequency ablation for saphenous vein reflux with 95%+ efficacy. Third, LaserBLOCK uses 1470nm endovenous laser ablation with reduced bruising compared to 980nm systems. Moreover, dedicated venous stents treat May-Thurner syndrome and post-thrombotic syndrome. These minimally invasive options reduce recovery time from weeks to 1-2 days.

What Is Mechanical Thrombectomy for DVT and Stroke?

Mechanical thrombectomy is a catheter-based procedure that physically removes blood clots from arteries or veins. For deep vein thrombosis (DVT), the Mantis platform offers three distinct approaches: rotational clot disruption, high-vacuum aspiration, and pharmacomechanical thrombolysis combining mechanical action with drug delivery. Additionally, MultiBEAM retrievable IVC filters protect high-risk patients against pulmonary embolism when anticoagulation is contraindicated. For acute ischemic stroke caused by large vessel occlusion, the KinG stent retriever captures and extracts cerebral artery clots within a treatment window of up to 24 hours. According to landmark trials published in the New England Journal of Medicine, mechanical thrombectomy improves functional independence by 20-30% compared to medical therapy alone. DVT affects approximately 1-2 per 1,000 adults annually in developed countries.

Why Choose ATLAS Drug-Eluting Coronary Stents?

The ATLAS drug-eluting stent uses a thin-strut (60 micrometer) cobalt-chromium L605 alloy platform. This design provides 9-10 atm nominal pressure with 14-16 atm burst pressure rating. The sirolimus coating at 1 microgram per mm2 prevents restenosis after PCI procedures. Clinical data shows target lesion revascularization rates below 5% at 12 months. In addition, INVAMED offers PTCA balloons (2.0-5.0mm diameters), CTO guidewires (1-20g tip stiffness range), and the TemREN rotablator for calcified lesions. Coronary artery disease affects approximately 126 million people globally, according to The Lancet.

How Does the STENA Multilayer Flow Modulator Work?

The STENA MFM is a unique branch-preserving aortic stent with a 3D braided multi-layer design. Unlike conventional stent grafts, it modulates blood flow without covering branch vessels. Therefore, it eliminates endoleak risk entirely. In a study of 55 patients, technical success rate was 98.2% with no perioperative paraplegia. Research published in the Journal of Vascular Surgery demonstrates its effectiveness for thoracoabdominal aortic aneurysms with mean diameter of 6.04 cm. Over 243 patients have been treated worldwide with the MFM technology.

What Embolization Devices Are Available?

INVAMED provides a comprehensive embolization portfolio used across international markets. MultiBEAM nitinol vascular plugs offer controlled vessel occlusion with 4-22mm diameter range. LIBRO EVOH liquid embolic agent (6% and 8% concentrations) treats cerebral AVMs and tumors with tantalum-enhanced fluoroscopic visibility. Furthermore, Spider platinum-tungsten (92/8% alloy) coils provide reliable aneurysm packing with 2-30mm coil diameters. The global embolization market reached $4.2 billion in 2025, according to Grand View Research.

What Orthopedic Implants Does INVAMED Offer?

The CytroFIX system includes 35+ orthopedic implant variants made from Ti-6Al-4V medical-grade titanium alloy. Intramedullary nails cover femoral (9-13mm diameter), tibial, and humeral fractures. Titanium locking plates are available in over 200 size configurations for clavicle, humerus, radius, femur, tibia, and pelvic fractures. Additionally, hip and knee replacement systems address degenerative joint disease affecting 595 million people worldwide according to The Lancet Global Burden of Disease Study.

Which Specialty Devices Does INVAMED Produce?

Beyond core product lines, INVAMED manufactures specialty devices for 8 additional medical fields. Urology products include hydrophilic double-J ureteral stents, percutaneous nephrostomy kits, and stone extraction baskets used in over 15,000 procedures annually. ENT solutions feature the Voltran intranasal phototherapy system, which treats allergic rhinitis using narrow-band UVB and infrared wavelengths without medication. Pain management devices include spinal cord stimulators for chronic pain neuromodulation and radiofrequency lesion generators for facet joint denervation. Moreover, the DENTURA titanium dental implant system achieves osseointegration rates exceeding 95% at 5 years. Digital health platforms such as the RhythmTrack mobile cardiac telemetry system enable remote arrhythmia detection and real-time ECG monitoring. Hemostatic solutions and aesthetic medicine devices complete the specialty portfolio.

How Does INVAMED Approach Research and Clinical Evidence?

INVAMED pairs engineering with clinical science at every stage. Device development follows guidance from the World Health Organization (WHO) medical devices program, and the company participates in research indexed on PubMed / National Library of Medicine. INVAMED operates in the United States through Standard Technology Solutions, Inc. at One World Trade Center, New York, and has received the GHP Medical Device Innovator of the Year award in both 2025 and 2026.